Sanket Mishra, Ph.D. is the co-founder and Vice President of Preclinical Research and Development at Grannus Therapeutics. He is the scientific inventor behind the company’s core technology: a novel class of isoform-selective Hsp90β inhibitors designed to overcome the toxicity limitations of earlier pan-Hsp90 therapies. Dr. Mishra has been central to the discovery, design, and early development of this innovative chemotype, which shows strong potential as a targeted cancer therapy. Dr. Mishra received his B.S. and M.S. in Pharmaceutical Sciences from the University of Mumbai, followed by a Ph.D. in Medicinal Chemistry from the University of Kansas. His doctoral work focused on structure-based drug design to develop selective Hsp90 inhibitors, culminating in the identification of a first-in-class molecule with high selectivity and potency for the Hsp90β isoform. Recognizing the translational promise of this work, he continued its advancement as a postdoctoral researcher at the University of Notre Dame, where he helped evolve the program into a viable therapeutic candidate. Dr. Mishra’s deep domain knowledge in Hsp90 biology, medicinal chemistry, and oncology drug discovery uniquely positions him to lead the scientific direction of Grannus.